CG Oncology, Inc.
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| CGON | IBRX | URGN | 2616.HK | SMMT | BNTX | |
|---|---|---|---|---|---|---|
| Market cap | 6.00B | 9.46B | 1.40B | 8.98B | 12.90B | 22.49B |
| P/E (TTM) | — | — | — | — | — | — |
| Forward P/E | -22.4 | -121.8 | 10.4 | 137.0 | -13.8 | -16.6 |
| Price/book | 5.8 | -9.0 | -13.2 | 5.9 | 19.0 | 1.1 |
| Dividend yield | — | — | — | — | — | — |
| 1-year change | +70.60% | +321.23% | +78.15% | −7.84% | −12.36% | −15.96% |
| Today | +5.70% | +7.72% | −16.45% | +4.16% | +2.34% | +4.35% |
The closest companies by business and industry (Biotechnology). Prices may be delayed up to 15 min.
Latest news
All CGON news ›Head-To-Head Comparison: CG Oncology (NASDAQ:CGON) and Alector (NASDAQ:ALEC)
Posted by Sarita Garza on Nov 2nd, 2026 CG Oncology (NASDAQ:CGON – Get Free Report) and Alector (NASDAQ:ALEC – Get Free Report) are both healthcare companies, but which is the better business? We will compare the two businesses based on…
CG Oncology: A Second-Mover Advantage In Bladder-Sparing Therapy
CG Oncology is well-positioned to enter a de-risked NMIBC market with cretostimogene. Click here to read why CGON stock is a Buy. - CG Oncology is well-positioned to enter a de-risked NMIBC market with cretostimogene, offering a clean…
CG Oncology grants Isabel Kalofonos 92,000 stock options
CG Oncology (NASDAQ: CGON) is a late-stage biopharma company developing cretostimogene, an intravesical oncolytic immunotherapy for non-muscle invasive bladder cancer. - [Form 4] CG Oncology, Inc. Insider Trading Activity CG Oncology…
CG Oncology director Post sells 1,000 shares
CG Oncology (NASDAQ: CGON) is a late-stage biopharma company developing cretostimogene, an intravesical oncolytic immunotherapy for non-muscle invasive bladder cancer. - [Form 4] CG Oncology, Inc. Insider Trading Activity CG Oncology…
[Form 3] CG Oncology, Inc. Initial Statement of Beneficial Ownership
Stock Titan - [Form 3] CG Oncology, Inc. Initial Statement of Beneficial Ownership Sentiment and the balance of points Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scal
CG Oncology director Leonard Post plans $186K share sale
A director plans to sell 3,000 shares of CG Oncology (NASDAQ: CGON). Stock Titan CG Oncology director Leonard Post plans $186K share sale The notice links the proposed sale to stock options expected to be exercised over the next three…
From the 4Search news index, newest first.
In the news
Mentioned with
People in the coverage
Themes
Most coverage from
- stocktitan.net4
- seekingalpha.com1
- themarketsdaily.com1
Finance and business coverage in the 4SEARCH.business news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 6 articles, not a forecast.